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Introduction: Non–small-cell lung cancer (NSCLC) is the lead-
ing cause of cancer-related morbidity and mortality. Unfortunately, 
patients with NSCLC have relatively poor survival rates compared 
with patients diagnosed with most other types of cancer. Accordingly, 
managing physical and mental health symptoms are important treat-
ment goals. In the current investigation, we sought to determine 
whether individual socioeconomic status (SES; as indexed by level 
of education), racial/ethnic minority status, and hospital type (pub-
lic versus tertiary care center) were associated with NSCLC cancer 
patients’ depressive severity. Importantly, we investigated whether 
NSCLC patients’ individual SES was more or less prognostic of their 
depressive severity compared with minority status and the hospital 
context where they received treatment.
Methods: Patients scheduled for chemotherapy were assessed for 
depressed mood by the Beck Depression Inventory-II (BDI-II). Data 
were collected at baseline and at approximately 6, 12, and 18 weeks.
Results: NSCLC patients with less education had more depres-
sive severity than those with more education. Treatment setting and 
minority status were not associated with depressive severity. The 
interaction between education level and treatment setting predicting 
depressive severity was not significant, suggesting that the associa-
tion between education level and depressive severity did not differ by 
treatment setting.
Conclusion: Our study brings heightened awareness to the sub-
stantial, persistent SES differences that exist in depressive severity 
among late-stage NSCLC patients. Furthermore, these findings seem 
to persist, regardless of minority status and whether the patient is 
treated at a public hospital or tertiary cancer center.
Key Words: Depression, Quality of life, Socioeconomic status, 
Non–small-cell lung cancer, Medically underserved.
(J Thorac Oncol. 2014;9: 1459–1463)
Health disparities increase with each step down the socio-economic status (SES) ladder.1 Whether indexed by edu-
cation, income, or job status, being low SES is associated with 
poor health.1 For most cancers, lower SES individuals are at 
greater risk for both incidence and mortality compared with 
those who are higher SES.2,3 Much less is known about how 
SES impacts cancer patients’ mental and physical well-being.
Non–small-cell lung cancer (NSCLC) is the leading 
cause of cancer-related morbidity and mortality.4 Unfortunately, 
patients with NSCLC have relatively poor survival rates com-
pared with patients diagnosed with most other types of cancer. 
Accordingly, managing physical and mental health symptoms 
are important treatment goals.5 To improve NSCLC patients’ 
quality of life (QOL), it is imperative to identify factors associ-
ated with physical and mental well-being.
Recently, we demonstrated that lower SES individuals 
(as indexed by level of education) with advanced NSCLC had 
poorer physical well-being (i.e., pain, fatigue, disturbed sleep, 
shortness of breath, and drowsiness) during chemotherapy 
compared with those who were higher SES.5 Likewise, NSCLC 
patients who were treated at public hospitals with good per-
formance status were more likely to experience these symp-
toms compared with those treated at a tertiary care centers.5 
Importantly, these findings persisted over 15 weeks of therapy.5
In the current investigation, we sought to determine 
whether SES, racial and ethnic minority status, and hospital 
type (pubic versus tertiary care center) were associated with 
NSCLC cancer patients’ depressive severity over 15 weeks of 
therapy. Depression severity is an important aspect of mental 
well-being and one of the strongest predictors of QOL for can-
cer patients.6 Cancer patients’ depression is also a major con-
tributor to their close family members’ well-being.7 Importantly, 
we investigated whether NSCLC patients’ individual SES was 
more or less prognostic of their depressive severity compared 
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with the hospital context where they received treatment and 
their status as a racial or ethnic minority.
STUDY PARTICIPANTS
Advanced stage (IIIB–IV) NSCLC patients who were 
scheduled for chemotherapy were recruited for this study 
between January 2004 and December 2008. They were 
recruited from thoracic medical oncology clinics of a ter-
tiary cancer center in Houston, Texas, and from the general 
oncology clinics of three public hospitals (two in Houston, 
one in Miami, Florida) providing care for medically under-
served (noninsured/underinsured and/or low-income) 
patients.8 The study was approved by the institutional 
review boards of the participating institutions. All patients 
gave informed consent to participate. The study time period 
was limited to the first 18 weeks of treatment based on a 
standard chemotherapy protocol that included six, 3-week 
cycles of treatment.
Of 234 eligible patients approached to participate in 
the study, 189 consented to participate. Four withdrew before 
baseline assessment, such that 185 were included in the final 
analysis. Of these, 102 were recruited from the tertiary cancer 
center and 83 from the public hospitals. All 185 patients con-
tributed data at baseline, 140 at 6 weeks, 107 at 12 weeks, and 
79 at 18 weeks from the start of the study (Fig. 1).
MEASURES
The Beck Depression Inventory II (BDI-II)9 is a widely 
used instrument for measuring the intensity of depression. It 
contains 21 items that assess various aspects of depression. 
Each item is rated on a 4-point scale, resulting in a maximum 
attainable score of 63. A higher total score indicates more-
severe depressive severity. The BDI-II has high clinical sen-
sitivity with a reliability coefficient of 0.92 and predictive 
validity of 0.91.9 Assessments were obtained at baseline and 
at 6, 12, and 18 weeks from initiation of chemotherapy using 
the BDI-II’s standard cut points.9 The BDI-II has been found 
to be a reliable measure of depression across race/ethnicity 
and gender.10,11
Comorbidities
The Charlson index is the most widely used comorbid-
ity index. Originally developed for predicting mortality in 
breast cancer patients, it has now been widely used with both 
cancer and noncancer populations.12
Demographic and Clinical Variables
Participants answered questions about their age, 
race, highest level of education, marital status, and gender. 
Following participants’ authorization, electronic medical 
records were reviewed to obtain initial treatment date.
Eligibility Criteria:
Stage IIIB/IV NSCLC, scheduled to 
begin chemotherapy
(N=234)
Consented and enrolled onto study 
(n=189)
Refused to participate
(n=45)
Tertiary Cancer Center
(n=20)
Public Hospitals
(n=25)
Tertiary Cancer Center
Baseline: n=102
6 weeks: n=73
12 weeks: n=47
18 weeks: n=29
Dropped before Baseline 
Assessment
(n=4)
Completed Baseline 
Assessment
(n=185)
Public Hospitals
Baseline: n=83
6 weeks: n=67
12 weeks: n=60
18 weeks: n=50
FIGURE 1.  Flow of participants through the study. NSCLC, Non–small-cell lung cancer.
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Educational level was used to assess the women in 
our sample as has been done in previous studies using can-
cer populations that included older adult women because it 
was difficult to know whether the women in our same sample 
worked outside the home.13 In addition, education is less vul-
nerable to fluctuations in current income and job status.14–16 
Participants reported number of years of formal schooling 
they had received to indicate level of education.
ANALYTIC METHOD
Education was modeled as a continuous variable, based 
on prior work showing that the association between SES and 
health is monotonic (i.e., the association between SES and health 
shows a gradient increase).17,18 Descriptive statistics, including 
means, standard deviations (SDs), and percentages, were used 
to describe patient demographics and clinical characteristics. 
Using mixed models regression, we addressed the question of 
whether SES (as indexed by level of education), minority sta-
tus, and hospital type were associated with depressive severity 
across visits. We used restricted information maximum likeli-
hood estimation to fit all models. Restricted information maxi-
mum likelihood is superior to listwise deletion for handling 
attrition.19 It performs well when data are missing at random 
and improves nonrandom circumstances over ignoring cases 
entirely.20 We used an unstructured within-subjects covariance 
matrix and examined the model residuals to confirm that they 
were distributed normally. We included education, visit, minor-
ity status, time since treatment, marital status, comorbidities, 
sex, age, and stage in the model. Age and depressive severity 
were time varying. All other variables were time invariant.
In ancillary analyses, we adjusted for cancer treatment 
rather than cancer stage (stage and treatment type are highly 
related and were not entered simultaneously to avoid multicol-
linearity); none of the results presented below changed. We also 
created a variable indicating if and when a patient dropped out 
at any time before the end of the study; we included this vari-
able in ancillary analyses to ensure it did not bias the results.
RESULTS
Preliminary Analyses
Patient demographic and clinical characteristics by treat-
ment site (tertiary versus public) are presented in Table 1. A 
higher proportion of patients at the tertiary center had stage IV 
disease. Patients at the tertiary center were more likely to be mar-
ried, have attended college, be employed, or be retired. Individuals 
who were lost to attrition did not significantly differ on any of the 
study variables compared with those who completed both visits. 
Those who were less educated were more likely to be treated at a 
public hospital compared with a tertiary cancer center (r = −0.42, 
p = 0.001). Across all visits and groups, 67.1% experienced 
minimal depressive severity, 18.8% experienced mild depressive 
severity, 9.0% experienced moderate depressive severity, and 
5.2% experienced severe depressive severity.
Analyses
As can be seen in Table 2, participants with more 
education had less depressive severity than those with less 
education. The interaction between education and time was 
not significant (b = −0.01, p = 0.61), demonstrating that the 
association between education and depressive severity did not 
differ across visits. Treatment setting was not associated with 
depressive severity. Likewise, treatment setting did not inter-
act with visit (b = −0.01, p = 0.25). Those who were mem-
bers of a racial/ethnic minority group did not experience more 
depressive severity than those who were not. To estimate the 
magnitude that depressive severity differed by level of edu-
cation between participants lower and higher in educational 
level, we used the covariate-adjusted means at 1 SD above and 
below the mean level of education. Participants with less edu-
cation (−1 SD) had 42.5% more depressive severity than those 
with more education (+1 SD).
TABLE 1.  Sample Characteristics by Treatment Site
Characteristic
Tertiary 
(n = 102)
Public  
(n = 83)
pNo. (%) No. (%)
Age
  Mean (yr) 61.3 58 0.012
  Standard deviation 9.4 8.1
Gender
  Men 67 (65.7) 49 (59.0) 0.352
  Women 35 (34.3) 34 (41.0)
Marital status
  Married 84 (82.4) 32 (38.6) <0.001
  Unmarried 18 (17.6) 51 (61.4)
Education level
  Mean (yr) 13.6 10.7 <0.001
  Standard deviation 3.1 3.3
Job status
  Employed outside the home 24 (24.0) 13 (15.7) <0.001
  Homemaker 8 (8.0) 3 (3.6)
  Retired 43 (43.0) 13 (15.7)
  Medical leave or disability 23 (23.0) 32 (38.6)
  Unemployed/other 2 (2.0) 22 (26.5)
Ethnicity
  Asian 0 (0.0) 1 (1.2) <0.001
  Black Non-Hispanic 7 (6.9) 38 (45.8)
  Hispanic 1 (1.0) 25 (30.1)
  White Non-Hispanic 94 (92.2) 19 (22.9)
Cancer stage
  IIIB 7 (6.9) 29 (34.9) <0.001
  IV 95 (93.1) 54 (65.1)
Previous treatment
  Chemotherapy 27 (26.5) 18 (21.7) 0.538
  Surgery 19 (18.6) 3 (3.6) 0.002
  Radiation 37 (36.3) 16 (19.3) 0.016
  Treatment naive 59 (57.8) 29 (34.9) 0.008
Charlson comorbidity score
  0 to 1 69 (68.3) 64 (81.0) 0.054
  2+ 32 (31.7) 15 (19.0)
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In ancillary analyses, we tested for the interaction 
between education level and treatment setting predict-
ing depressive severity and it was not significant (b = 0.01, 
p = 0.66). Finally, we adjusted for dropout by including a 
covariate that modeled number of time points completed. 
Educational level was still associated with depressive sever-
ity (b = −0.07, p = 0.04), while treatment setting was not 
(b = 0.22, p = 0.22).
DISCUSSION
Higher SES (as indexed by education) NSCLC patients 
had less depressive severity than those who were lower SES. 
This association persisted irrespective of whether or not the 
patients were members of an ethnic or racial minority group. 
It also persisted regardless of whether the patients were treated 
at a public hospital or a tertiary cancer center. NSCLC patients 
treated at tertiary cancer centers were no less likely to experi-
ence elevated levels of depressive severity than those treated 
at public hospitals.
Previous studies have reported that medically under-
served cancer patients are more likely to experience depres-
sion compared with others.21,22 However, this is the first 
study, to our knowledge, to compare the impact of patients’ 
individual SES relative to their treatment context. This is 
particularly important, given our prior work that demon-
strated that treatment context (i.e., public versus tertiary 
cancer center) was a major factor associated with NSCLC 
patients’ physical well-being as indexed by a composite 
symptom burden index.5
There are several factors that may explain the associa-
tion between SES and depressive severity among NSCLC 
patients. As previously reported, those who are low SES expe-
rience more physical symptoms compared with those who 
are higher SES.5 Physical symptoms can enhance depressive 
severity.23 Furthermore, lower SES individuals do not ben-
efit from same quality of social support as higher SES indi-
viduals because their support network has many competing 
demands.13 High-quality social support is one of the most 
effective ways to buffer against stress and depression during a 
stressful life event.24,25
Depression is a risk factor for mortality among NSCLC 
patients such that those who were depressed had twice the risk 
of death compared with nondepressed patients.26 Recent work 
demonstrated that interventions aimed at improving depres-
sive severity and symptom control among those with NSCLC 
may also promote longer survival.27 These interventions may 
be particularly beneficial for low SES individuals.
This study has several limitations. First, it included 
patients from a single tertiary center; thus, generalization of 
our results to other tertiary centers is not warranted. Second, 
it did not include patients from community care settings. It 
would be interesting for future studies to use income and job 
status in addition to education to evaluate SES. Finally, this 
study included patients with advanced NSCLC only; thus, 
results may not be generalizable to patients with other types 
of cancer or less advanced disease. Future studies to assess 
patients’ depression should include longitudinal designs and 
incorporate patients from multiple public, community, and 
tertiary care centers.
Our study brings heightened awareness to the substan-
tial, persistent SES differences that exist in depressive severity 
among late-stage NSCLC patients. Clinicians in all treatment 
facilities should screen for depression and institute early and 
appropriate management. These interventions may improve 
QOL and even impact survival time.27–31
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